|
PRPF8 expression based on
|
| Comparison | Statistical significance |
| Normal-vs-Primary | 4.05599999997452E-06 |
|
Note
Cancer stage information is not available for 2 samples.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Stage1 |
3.79470000000381E-05 |
| Normal-vs-Stage2 |
8.129800E-02 |
| Normal-vs-Stage3 |
8.76790000048366E-07 |
| Normal-vs-Stage4 |
5.68389999999752E-05 |
| Stage1-vs-Stage2 |
1.028840E-01 |
| Stage1-vs-Stage3 |
2.570200E-01 |
| Stage1-vs-Stage4 |
4.618400E-01 |
| Stage2-vs-Stage3 |
3.681900E-02 |
| Stage2-vs-Stage4 |
6.540100E-02 |
| Stage3-vs-Stage4 |
9.068600E-01 |
|
|
Note
Patient race information is not available for 92 samples and one samples from American Indians not included in the above plot.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Caucasian |
3.88920000005122E-06 |
| Normal-vs-AfricanAmerican |
1.338170E-01 |
| Normal-vs-Asian |
2.164500E-03 |
| Caucasian-vs-AfricanAmerican |
1.400970E-01 |
| Caucasian-vs-Asian |
7.888200E-01 |
| AfricanAmerican-vs-Asian |
2.856200E-01 |
|
|
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Male |
1.20869999997719E-06 |
| Normal-vs-Female |
5.54720000000009E-05 |
| Male-vs-Female |
2.250400E-01 |
|
|
Note
Seventeen samples from patient below 21 years not considered in above plot.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Age(21-40Yrs) |
9.67099999999999E-05 |
| Normal-vs-Age(41-60Yrs) |
5.85180000000074E-05 |
| Normal-vs-Age(61-80Yrs) |
4.23510000000515E-05 |
| Normal-vs-Age(81-100Yrs) |
1.844090E-02 |
| Age(21-40Yrs)-vs-Age(41-60Yrs) |
7.463200E-01 |
| Age(21-40Yrs)-vs-Age(61-80Yrs) |
8.135600E-01 |
| Age(21-40Yrs)-vs-Age(81-100Yrs) |
5.852400E-01 |
| Age(41-60Yrs)-vs-Age(61-80Yrs) |
9.548800E-01 |
| Age(41-60Yrs)-vs-Age(81-100Yrs) |
6.760400E-01 |
| Age(61-80Yrs)-vs-Age(81-100Yrs) |
6.078600E-01 |
|
|
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Classical-VS-Tall |
3.133600E-02 |
| Classical-VS-Follicular |
3.448400E-02 |
| Classical-VS-Other |
7.156300E-02 |
| Classical-VS-Normal |
3.033600E-04 |
| Tall-VS-Follicular |
4.728400E-01 |
| Tall-VS-Other |
4.436400E-01 |
| Tall-VS-Normal |
2.31899999999508E-05 |
| Follicular-VS-Other |
3.508400E-01 |
| Follicular-VS-Normal |
3.84680000000692E-05 |
| Other-VS-Normal |
2.562100E-03 |
|
|
Note
Cancer in nearby lymph nodes cannot be measured (NX) in 50 samples.
| pathologic_N descriptions |
| N0 | No regional lymph node metastasis |
N1 | Metastases in 1 to 3 axillary lymph nodes |
| N2 | Metastases in 4 to 9 axillary lymph nodes |
N3 | Metastases in 10 or more axillary lymph nodes |
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-N0 |
8.10810000000384E-05 |
| Normal-vs-N1 |
1.11700000005044E-06 |
| N0-vs-N1 |
7.527900E-02 |
|
|
